Seer

Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. Its Proteograph product suite comprises automation instrument and software, which provides workflow to make proteomic profiling. The company was founded by Philip Ma, Robert S. Langer Jr. and Omid C. Farokhzad on March 16, 2017 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seer reports strong Q4 earnings, eyes revenue growth in 2023

Seer's Q4 2022 earnings reflect robust growth, driven by product sales and service projects. While challenges persist in China market access, the company is poised for revenue growth in 2023 through consumables and service contracts.

Seer (SEER) reports strong Q1 revenue growth and technology validation

Seer's Q1 performance showed revenue growth and a focus on disciplined expense management for financial strength.
The company's emphasis on Proteograph technology and customer validation positions it well for future growth.
While facing challenges in sales cycles and market opportunities, Seer is leveraging strategic initiatives for growth.

Seer reports revenue growth amidst challenges, focuses on strategic initiatives

Seer's Q2 performance showed revenue growth but faced a net loss due to operating expenses, prompting strategic cost management and sales cycle improvements.
Strengths lie in product expansion, strategic collaborations, and a focus on consumable margins, positioning Seer well in the proteomics market.
Challenges in adoption and cost alignment require focused efforts, while opportunities in customer engagement and strategic programs offer growth potential.

Seer reports Q3 revenue growth amidst macro challenges and partnerships

Seer's Q3 performance showed revenue growth but with a net loss, ending the quarter with a strong cash position. The company faces challenges from macroeconomic uncertainty impacting revenue and sales cycles. Seer's initiatives and partnerships present opportunities for growth and market adoption.

Seer reports revenue growth in 2023, eyes innovation for 2024

Seer's 2023 performance showed revenue growth and cost management improvements, ending the year well-funded.
Strong demand for technology and programs, coupled with a focus on innovation and evidence, positions Seer for growth.
Challenges in China and Europe markets require strategic navigation, while opportunities lie in revenue growth and technology advancements.

Seer reports Q1 revenue of $3.1M, focuses on innovation and cost-saving

Seer's Q1 2024 performance reflected revenue of $3.1 million, with cost-saving measures leading to reduced operating expenses. The company faces challenges in revenue growth due to slow platform adoption but is leveraging strengths in innovative technology and research support programs. Strategic initiatives like market share repurchase and global expansion present opportunities for future growth.

Seer reports revenue growth and strategic partnerships amid profitability challenges

Seer's Q3 performance reflects revenue growth and strategic collaborations despite financial losses.
The company's strong cash reserves and partnerships signal resilience and potential for market expansion.
While facing profitability challenges, Seer's innovative technology and market demand offer growth opportunities.
Navigating market uncertainties and optimizing financial performance are key focus areas for Seer.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seer, Inc. (SEER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seer, Inc. (SEER) Moves to Buy: Rationale Behind the Upgrade

Seer, Inc. (SEER) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seer, Inc. (SEER) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Cowen 43rd Annual Health Care Conference in Boston, MA.

Seer to Present at the Cowen 43rd Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2022, after market close, on Thursday, March 2, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Seer to Present at the J.P. Morgan 41st Annual Health Care Conference

Olink Holding AB

Creates a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis to support drug and diagnostic development HUNTSVILLE, Ala. , Dec. 14, 2022 /PRNewswire/ --  Discovery Life Sciences™  (Discovery) today announced the launch of its new Proteomic Services Division and is now accepting samples from pharmaceutical and biotech companies, government, and non-profit and academic research centers.

DISCOVERY LIFE SCIENCES LAUNCHES WORLD-CLASS PROTEOMIC SERVICES DIVISION SUPPORTED BY LEADING TECHNOLOGY PARTNERS

Annual award from The Scientist celebrates transformative products like Seer's Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible Annual award from The Scientist celebrates transformative products like Seer's Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible

Seer's Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist

Seer, Inc. (NASDAQ:SEER ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - Chair and CEO David Horn - CFO Conference Call Participants Dan Brennan - Cowen Derik De Bruin - Bank of America Neel Ram - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Seer Inc. Third Quarter 2022 Earnings Call.

Seer, Inc. (SEER) CEO Omid Farokhzad on Q3 2022 Results - Earnings Call Transcript

Proteograph utility is demonstrated as market interest continues to build with multiple studies underway Proteograph utility is demonstrated as market interest continues to build with multiple studies underway

Seer Reports Third Quarter 2022 Financial Results

REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the third quarter of 2022 on Tuesday, November 8, 2022. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Third Quarter 2022 Financial Results on November 8, 2022

REDWOOD CITY, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York City, New York.

Seer to Participate in the Morgan Stanley Global Healthcare Conference

Published results highlight how the combination of proteomic methods, nanoengineering and machine learning enables the capture of thousands of proteins Published results highlight how the combination of proteomic methods, nanoengineering and machine learning enables the capture of thousands of proteins

Seer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome

Seer, Inc. (NASDAQ:SEER ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - Founder, Chairman & CEO David Horn - CFO Omead Ostadan - President Conference Call Participants Derik De Bruin - Bank of America Neel Ram - Morgan Stanley Kyle Boucher - Cowen Operator Ladies and gentlemen, thank you for standing by, and welcome to the Seer Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Seer, Inc. (SEER) CEO Omid Farokhzad on Q2 2022 Results - Earnings Call Transcript

Seer, Inc. (SEER) delivered earnings and revenue surprises of 5.13% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Seer, Inc. (SEER) Reports Q2 Loss, Tops Revenue Estimates

Company launches novel proteogenomics workflow with the Proteograph™ Analysis Suite 2.0, further demonstrates the power of its technology with new customer data, and advances key partnerships Company launches novel proteogenomics workflow with the Proteograph™ Analysis Suite 2.0, further demonstrates the power of its technology with new customer data, and advances key partnerships

Seer Reports Second Quarter 2022 Financial Results

Scalable, high-resolution, sample-specific analysis brings genomics and proteomics together to enable novel biological insights with the click of a button Scalable, high-resolution, sample-specific analysis brings genomics and proteomics together to enable novel biological insights with the click of a button

Seer Launches First-of-its-kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograph™ Analysis Suite 2.0

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the second quarter of 2022 on Tuesday, August 9, 2022. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Second Quarter 2022 Financial Results on August 9, 2022

Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Seer, Inc. (SEER) Stock Jumps 12.9%: Will It Continue to Soar?

Seer, Inc. (NASDAQ:SEER ) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - Founder, Chairman & CEO David Horn - CFO Omead Ostadan - President Conference Call Participants Neil Vibhakar - Morgan Stanley Nisarg Shah - Bank of America Merrill Lynch -- Analyst Kyle Boucher - Cowen and Company Operator Good day and thank you for standing by. Welcome to the Seer, Inc. First Quarter 2022 Earnings Conference Call.

Seer, Inc. (SEER) CEO Omid Farokhzad on Q1 2022 Results - Earnings Call Transcript

Demonstrated solid commercial traction with continued robust interest in the Proteograph Product Suite Demonstrated solid commercial traction with continued robust interest in the Proteograph Product Suite

Seer Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.

Seer to Present at the BofA Securities 2022 Healthcare Conference

Seer, Inc. (SEER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Seer, Inc. (SEER) to Report a Decline in Earnings: What to Look Out for

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter of 2022 on Wednesday, May 4, 2022. Company management will be webcasting a conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.

Seer to Report First Quarter Financial Results on May 4, 2022

NEW YORK , April 5, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Seer, Inc. (NASDAQ: SEER) resulting from allegations that Seer may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Seer securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Seer, Inc. Investors With Losses to Inquire About Class Action Investigation - SEER

New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Seer, Inc. (NASDAQ: SEER) resulting from allegations that Seer may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Seer securities you may be entitled to compensation without payment of any out of pocket fees or costs through...

SEER SHAREHOLDER ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Seer, Inc. Investors with Losses to Inquire About Class Action Investigation - SEER

News for Seer Stock (SEER)